MyPharmaGenes®

DNA test to guide individual drug therapy

Comprehensive DNA test for the definition of personalized medication strategies.

PHARMACOGENETICS: VARIABILITY IN DRUG RESPONSE

Genetics contributes to individual differences not only in physical characteristics, but also at the pharmacological level. Pharmacogenetics studies the relationship between genetic variability and how individuals respond to drugs. This information supports doctors in therapeutic decision-making, including the selection of active compounds and the adjustment of doses, with the goal of maximising therapeutic effects and minimising the risk of adverse reactions.

What mypharmagenes® analyses?

The test evaluates genetic variants associated with the metabolism and response to specific drugs, selected on the basis of scientific validation and proven clinical utility. The analysis covers 15 genes and 85 genetic variants, with results informing clinical decisions across 114 commonly prescribed medications.

Identification of the patient’s genotypic profile in relation to drug metabolism

Support for more adequate drug dosage prescription

Assessment of the patient’s likely response to treatment

Guidance on avoiding or minimising adverse drug reactions

Basis for selecting alternative therapeutic agents when necessary

Therapeutic areas covered:

Psychiatry

Neurology

Pain management

Cardiology

Oncology

Gastroenterology

Immunosuppression

Rheumatology

Urology

Infectiology

clinical indications:

MyPharmaGenes® may be indicated in the following clinical contexts:

Prior to initiating new pharmacological therapies
In patients who have not achieved therapeutic goals with current treatment
In patients experiencing moderate to severe adverse effects

An interactive WebApp included with the test

MyPharmaGenes® is supported by an interactive WebApp that provides patients and their healthcare professionals with ongoing access to the genetic report. It is designed to facilitate the practical application of pharmacogenetic results in clinical settings.

Consultation of pharmacogenetic results for all 114 covered drugs
Management of the patient’s current medication portfolio
Recording of drugs associated with adverse effects
Detailed information on the genes and variants evaluated

Drugs evaluated by therapeutic areA

: Amitriptyline, Amoxapine, Amphetamine, Aripiprazole, Atomoxetine, Brexpiprazole, Bupropion, Citalopram, Clobazam, Clomipramine, Desipramine, Diazepam, Doxepin, Escitalopram, Flibanserin, Fluvoxamine, Haloperidol, Iloperidone, Imipramine, Nortriptyline, Paroxetine, Perphenazine, Pimozide, Protriptyline, Quetiapine, Risperidone, Sertindole, Sertraline, Thioridazine, Trimipramine, Venlafaxine, Vortioxetine, Zuclopenthixol
: Brivaracetam, Carbamazepine, Deutetrabenazine, Donepezil, Eliglustat, Phenytoin, Fosphenytoin, Galantamine, Lamotrigine, Meclizine, Oxcarbazepine, Pitolisant, Siponimod, Tetrabenazine, Tolperisone, Valbenazine
: Carisoprodol, Celecoxib, Codeine, Flurbiprofen, Hydrocodone, Ibuprofen, Lofexidine, Lornoxicam, Meloxicam, Oliceridine, Piroxicam, Tenoxicam, Tramadol
: Acenocoumarol, Atorvastatin, Clopidogrel, Phenprocoumon, Flecainide, Fluvastatin, Losartan, Lovastatin, Mavacamten, Metoprolol, Pitavastatin, Pravastatin, Propafenone, Ranolazine, Rosuvastatin, Simvastatin, Warfarin
: Capecitabine, Cisplatin, Erlotinib, Fluorouracil, Irinotecan, Mercaptopurine, Ondansetron, Pazopanib, SN-38, Tamoxifen, Tegafur, Thioguanine, Tropisetron
: Dexlansoprazole, Dronabinol, Lansoprazole, Metoclopramide, Omeprazole, Pantoprazole
: Azathioprine, Tacrolimus
: Allopurinol, Lesinurad
: Darifenacin, Fesoterodine, Mirabegron, Tamsulosin, Tolterodine
: Abacavir, Atazanavir, Efavirenz, Flucytosine, Flucloxacillin, Nevirapine, Voriconazole

Turnaround time

15 working days

Click here to contact sales

Scientific Studies

[1] Bouvy, J.C., De Bruin, M.L. & Koopmanschap, M.A. “Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies”. Drug Saf 38 (2015): 437–453.
[2] Steve Connor (2003) “Glaxo chief: Our drugs do not work on most patients”, Independent/UK, 8/12/2003.
[3] Spear, B.B., Heath-Chiozzi, M. & Huff, J., “Clinical Application of Pharmacogenetics”. Trends Mol Med 7.5 (2001):201-204.
[4] Böhm, R. & Cascorbi, I., “Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions”. Front Pharmacol 7 (2016): 396.
[5] Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. “Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments”. AAPS J 20.1 (2018): 4.
[6] Gaedigk, Andrea, et al. “Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles: A GeT-RM Collaborative Project”. J Mol Diagn 21.6 (2019): 1034-1052.